Last reviewed · How we verify

Short Acting Methylphenidate

BRC Operations Pty. Ltd. · FDA-approved active Small molecule

Short-acting methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse.

Short-acting methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.

At a glance

Generic nameShort Acting Methylphenidate
Also known as• Ritalin, • Ritalina, • Attenta, • Methylin, • Penid
SponsorBRC Operations Pty. Ltd.
Drug classSympathomimetic amine; CNS stimulant
TargetDopamine transporter (DAT); Norepinephrine transporter (NET)
ModalitySmall molecule
Therapeutic areaNeurology; Psychiatry
PhaseFDA-approved

Mechanism of action

Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters (DAT and NET) for dopamine and norepinephrine, leading to increased neurotransmitter concentration in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The short-acting formulation reaches peak plasma levels within 1–3 hours and has a duration of action of 3–5 hours.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results